Active Not Recruiting INTERVENTIONAL NCT05192382

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) (PATHFNDR-2)

A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)

Sponsor: Crinetics Pharmaceuticals Inc.

Conditions Acromegaly

Interventions Paltusotine Placebo

Updated 21 times since 2022 Last updated: Apr 21, 2026 Started: Dec 17, 2021 Primary completion: Jan 20, 2024 Completion: Jan 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Acromegaly and is currently ongoing. Crinetics Pharmaceuticals Inc. leads this study, which shows 21 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

21 versions recorded

Apr 28, 2026 — Present [daily]

Active Not Recruiting

Phase: PHASE3 → None
Mar 2026 — Apr 2026 [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 16 earlier versions

Apr 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
Oct 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jul 2023 — Oct 2023 [monthly]

Recruiting PHASE3
May 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Jun 2022 [monthly]

Recruiting PHASE3

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

Contact Information

Sponsor contact:

Crinetics Pharmaceuticals Inc.

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Athens, Greece , Athens, Greece , Aurora, United States , Bangalore, India , Barcelona, Spain , Beijing, China , Belagavi, India , Belo Horizonte, Brazil , Berlin, Germany and 47 more locations